ACE.ST
Ascelia Pharma AB (publ) [ACE.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACE.ST Stock Summary
In the News
ACE.ST Financial details
Company Rating
-
Market Cap
388.89M
Income
-109.29M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
24
Optionable
No
Shortable
Yes
Earnings
16 May 2024
P/E
-1.4
Forward P/E
-
PEG
0.78
P/S
-
P/B
2.51
P/C
-
P/FCF
-1.16
Quick Ratio
1.82
Current Ratio
2.24
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.2
EPS next Y
-
EPS next Q
-
EPS this Y
-16.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-50.79%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-66.67%
Inst Own
-
Inst Trans
-
ROA
-143%
ROE
-118%
ROC
-1.79%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.62-17.5
52W High
-95.18%
52W Low
-59%
RSI
72
Rel Volume
5.14
Avg Volume
227.69K
Volume
1.17M
Perf Week
32.26%
Perf Month
34.43%
Perf Quarter
-73.03%
Perf Half Y
-74.53%
-
-
-
-
Beta
1.08
-
-
Volatility
0.08%, 0.06%
Prev Close
2.63%
Price
0.82
Change
4.19%
Company Profile
- Volume Average 227.69K
- Market Capitalization 388.89M
- Employee 24
- CEO Mr. Magnus O. Corfitzen
- Headquarters Malmö,SE
- IPO Date 2019-03-13
-
Website
https://www.ascelia.com 
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
